Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by an
educational grant from
Lung cancer is the second most common cancer in both men and women,
according to the American Cancer Society. It accounts for about 15%
of all new cancers, and during 2020, it was expected that there were
about 222,500 new cases of lung cancer. Non small-cell lung cancer (NSCLC)
accounts for approximately 80% of all lung cancer cases. Lung cancer
is by far the leading cause of cancer death among both men and
women, and there were an estimated 155,870 deaths from lung cancer
in 2020, accounting for around 29% of all cancer deaths. More people
die of lung cancer than of colon, breast, and prostate cancers
combined. Recent clinical data have demonstrated that NSCLC is a
very heterogeneous disease. However, as more comprehensive
information has been gathered regarding tumor characterization,
treatment modalities for NSCLC have expanded to include agents with
more specific targets. The use of histologic subtypes and molecular
biomarker assessment in NSCLC has resulted in therapeutic paradigms
that can be optimized for individual patients based on unique
characteristics of their cancer. Fortunately for patients with
metastatic NSCLC, immune checkpoint inhibitors have become available
in recent years, with more coming soon, that have showed improved
efficacy, safety and outcomes, especially in patients with high
levels of PD-L1 expression.
As more immunotherapies are becoming available, the treatment
paradigm has grown expansive, making it difficult for clinicians and
managed care professionals to make the appropriate decisions based
on recent clinical data and guidelines. In this program on NSCLC,
medical directors, oncologists, and nurses will learn about the
optimal use of current and emerging immunotherapy treatment options
and new options that are just becoming available, ultimately helping
patients achieve a greater quality of life and improved clinical and
Upon completion of this
activity, participants will be able to:
Analyze the rationale underlying the
use of immune checkpoint inhibition-based strategies for the
management of advanced NSCLC
Evaluate key clinical data on the
use of current and emerging checkpoint inhibitors in the
first-line treatment of squamous or nonsquamous advanced NSCLC
Compare and contrast safety and
efficacy profiles of current and emerging immunotherapies, both
alone and in combination, in the management of advanced NSCLC
Evaluate novel IO-associated
progression patterns and strategies for their appropriate
monitoring and treatment
Assess strategies for anticipating,
recognizing, and managing immune-related adverse events of
immune checkpoint inhibitors in advanced NSCLC
||Mark A. Socinski, MD
Executive Medical Director
AdventHealth Cancer Institute
Socinski has received research/grant support from
AstraZeneca, Genentech, Novartis, Spectrum, Mirati,
Cullinan, Daiichi-Sankyo, and Beigene. He serves on the
speaker’s bureau for AstraZeneca, Genentech, Novartis,
MD has no financial relationships with ineligible
companies to disclose.
Jeremy Williams has no financial relationships with
ineligible companies to disclose.
Jacqueline Cole, RN, MS, CMCN has no financial
relationships with ineligible companies to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
This activity is supported by an educational grant from
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue